메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Re…

SHANGHAI, Jan. 29, 2026 -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today revealed in 2026 ASCO abstract submission about the Phase Ib/II Clinical Data of its Q-1802 program. The report（Abstract #537934）is titled "PhaseⅠ/Ⅱ Trial of Anti-CLDN18.2/PD-L1 Recombinant Humanized Bispecific Antibody Q-1802 Plus XELOX in Treatment-Naive CLDN18.2-Positive Advanced GC/GEJ" The authors, Dr. Gong et al, reported the
- 김갑성 기자
- 2026-01-29 10:21
SK bioscience Initiates International Phase 1/2 Clinical Trial…

Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine strategy centered on universal vaccines for future pandemic preparedness INCHEON, South Korea, Jan. 29, 2026 -- SK bioscience announced the initiation of a global Phase 1/2 clinical trial in Australia for GBP511, a vaccine candidate targeting the sarbecovirus subgenus. Sarb
- 김갑성 기자
- 2026-01-29 10:10
Nona Biosciences Co-founds Innovative Alliance for Trans…

CAMBRIDGE, Mass., Jan. 29, 2026 -- Recently, as a core co-founder and co-organizer, Nona Biosciences participated in the launch of the "Innovative Alliance for Translational Medicine in Immunological Diseases" (the "Alliance") and attended its inauguration ceremony. The Alliance brings together stakeholders across industry, investment, research, and clinical practice to advance cutting-edge translational research and clinical exploration in immunological diseases, including investigator-initiated trials (IITs). The Alliance was jointly founded
- 김갑성 기자
- 2026-01-29 09:00
韓国大統領が高市首相に贈った「高麗人参」に注目集まる

[ 메디채널 김갑성 기자 ] 東京、2026年1月29日 -- 奈良県で開催された高市早苗首相と李在明大統領による日韓首脳会談が成功裏に終了し、両国が「経済・安全保障分野を含む多角的な協力」を今後も継続していく意向で一致したことが注目を集めている。今回の首脳会談では、会談内容に加え、両首脳が交換した記念品にも関心が寄せられている。両国首脳が互いの健康や関心事に配慮した贈り物を選んだことが、外交的メッセージをより印象づけたとの評価が広がっている。報道によると、李在明大統領は、高市首相の健康を願い、韓国を代表する健康食品ブランドである「正官庄（チョンガンジャン）高麗人参」を贈呈したほか、高校時代からドラマーとして活動してきた高市首相の経歴にちなみ、ドラムセットも贈ったという。一方、高市首相は、李大統領の趣味である登山に配慮し、日本を代表する時計ブランド CASIO の腕時計を贈呈した。特に注目されている「正官庄高麗人参」は、韓国を代表する健康食品ブランドとして、これまで国賓や海外首脳への贈答品として長年使用されてきた。過去には、ローマ教皇ヨハネ・パウロ2世、フランソワ・ミッテラン元フランス大統領、エリザベス2世英国女王など、世界各国の要人が韓国を訪問した際にも高麗人参が贈られており、昨年韓国で開催されたAPEC首
- 김갑성 기자
- 2026-01-29 08:00
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illucci…

MELBOURNE, Australia, Jan. 29, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Japanese patients. The patient was dosed at Shonan Kamakura General Hospital (SKGH) in Kamakura, Japan. Illuccix Japan[1] is a Phase 3 prospective, open-label, multicenter study designed to evaluate the detection efficacy and safety profile of 68Ga-PSMA-11 PET/CT[2] in
- 김갑성 기자
- 2026-01-29 07:43
REPROCELL Launches StemEdit - Clinical Gene Editing Service…

BELTSVILLE, Md., Jan. 29, 2026 -- REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEdit encompasses REPROCELL's proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL's StemRNA™ Clinical iPSC Seed Clones, with OpenCRISPR-1™ enabled engineering workflows, ensuring a GMP-aligned, traceable, a
- 김갑성 기자
- 2026-01-28 22:00
Global Appeal 2026: Education as the Key to Ending Lepros…

[ 메디채널 김갑성 기자 ] — Launch Event in Brussels Will Be Live-Streamed Worldwide — TOKYO, Jan. 28, 2026 -- The transformative power of education in replacing fear with knowledge and prejudice with empathy lies at the heart of the Global Appeal 2026 to End Stigma and Discrimination against Persons Affected by Leprosy. The appeal will be launched at a ceremony in Brussels, Belgium, on Thursday, 29 January 2026. The event is being co-hosted by Education International and the Sasakawa Leprosy (Hansen's Disease) Initiative, in partnership with the Damien Foundation. Since
- 김갑성 기자
- 2026-01-28 21:00
Samsung Biologics receives EcoVadis Platinum, the highes…

Ranked in the top one percent among more than 150,000 companies assessed globally Recognized for strengthened sustainability management across all four assessment categories INCHEON, South Korea, Jan. 28, 2026 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has received the EcoVadis' Platinum Sustainability Rating, the highest level of recognition for corporate sustainability performance. The Platinum rating places Samsung Biologics in the top one percent of companies eval
- 김갑성 기자
- 2026-01-28 20:00
Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial R…

HANGZHOU, China, Jan. 28, 2026 -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Conducted in adult T2DM patients with inadequate glycemic control after diet and exercise intervention, the results demonstrate that ecnoglutide injection — potentially the world's first long-acting cAMP-biased GLP-1 receptor agonist — significantly lowers blood glucose while also showing comprehensive bene
- 김갑성 기자
- 2026-01-28 19:39
CHCC 2026 Opens Registration, Offering a One-Stop Platform for H…

TIANJIN, China, Jan. 28, 2026 -- The 27th China Hospital Construction Conference & International Hospital Build and Infrastructure Exposition (CHCC 2026), a globally recognized hospital construction event, will be held from May 23 to 25, 2026, at the National Convention and Exhibition Center (Tianjin), China. Having been held successfully for 26 consecutive editions, CHCC has evolved into a widely recognized industry platform in the hospital construction sector, bringing together academic insights and industry practice. The event offers a one-stop platform for healthcare infrastruc
- 김갑성 기자
- 2026-01-28 15:01

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 13시 40분